Drugs / Moderna mRNA COVID-19 vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05028374 | Aug → Nov 2021 | AL amyloidosis, B-cell chronic lymphocytic leukemia, plasma cell myeloma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05212610 | Mar 2022 → Mar 2025 | COVID-19 | University of Michigan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moderna mRNA COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028374 ↗ |
| Modality | Vaccine | “Moderna mRNA COVID-19 vaccine” NCT05028374 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05028374 ↗ |